Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 6/2008

01-06-2008 | Original Article

Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway

Authors: Birgit Meller, Erzsébet Gaspar, Wibke Deisting, Barbara Czarnocka, Manfred Baehre, Björn E. Wenzel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2008

Login to get access

Abstract

Purpose

In radioiodine therapy the “stunning phenomenon” is defined as a reduction of radioiodine uptake after diagnostic application of 131I. In the current study, we established an in vitro model based on the “Fisher rat thyrocyte cell line no. 5” (FRTL-5) to investigate the stunning.

Methods

TSH-stimulated FRTL-5 cells were incubated with 131I. Time-dependent 131I uptake and the viability of FRTL-5 cells were evaluated at 4–144 h after radioiodine application. All data was corrected for number of viable cells, half life and 131I concentration. Sodium iodide symporter (NIS) and the housekeeping gene (β-actin, GAPDH) levels were quantified by quantitative polymerase chain reaction (qPCR). Additionally, immunohistochemical staining (IHC) of NIS on the cell membrane was carried out.

Results

FRTL-5 monolayer cell cultures showed a specific maximum uptake of 131I 24–48 h after application. Significantly decreased 131I uptake values were observed after 72–144 h. The decrease in radioiodine uptake was correlated with decreasing mRNA levels of NIS and housekeeping genes. In parallel, unlike in controls, IHC staining of NIS on FRTL-5 cells declined significantly after 131I long-term incubation.

Conclusions

It could be demonstrated that during 131I incubation of FRTL-5 cells, radioiodine uptake decreased significantly. Simultaneously decreasing levels of NIS mRNA and protein expression suggest a NIS-associated mechanism. Since mRNA levels of housekeeping genes decreased, too, the reduced NIS expression might be provoked by a cell cycle arrest. Our investigations recommend the FRTL-5 model as a valuable tool for further molecular biological investigations of the stunning phenomenon.
Literature
1.
go back to reference Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 2000;41:198–02. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 2000;41:198–02.
2.
go back to reference Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med. 2002;29:783–8.CrossRef Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med. 2002;29:783–8.CrossRef
3.
go back to reference Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–25.PubMed Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–25.PubMed
4.
go back to reference Lees W, Mansberg R, Roberts J, Towson J, Chua E, Turtle J. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging. 2002;29:421–7. Lees W, Mansberg R, Roberts J, Towson J, Chua E, Turtle J. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging. 2002;29:421–7.
5.
go back to reference Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371–7.PubMedCrossRef Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371–7.PubMedCrossRef
6.
go back to reference Medvedec M. Seeking a radiobiological explanation for thyroid stunning. Eur J Nucl Med. 2001;28:393–5.PubMedCrossRef Medvedec M. Seeking a radiobiological explanation for thyroid stunning. Eur J Nucl Med. 2001;28:393–5.PubMedCrossRef
7.
go back to reference Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507–11.PubMedCrossRef Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507–11.PubMedCrossRef
8.
go back to reference Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49–54.PubMed Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49–54.PubMed
9.
go back to reference Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34:1012–7.PubMedCrossRef Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34:1012–7.PubMedCrossRef
10.
go back to reference Wu HS, Hseu HH, Lin WY, Wang SJ, Liu YC. Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging. 2005;32:67–73.CrossRef Wu HS, Hseu HH, Lin WY, Wang SJ, Liu YC. Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging. 2005;32:67–73.CrossRef
11.
go back to reference Verburg FA, de Keizer B, Lips CJM, Zelissen PMJ, de Klerk JMH. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152:33–7.PubMedCrossRef Verburg FA, de Keizer B, Lips CJM, Zelissen PMJ, de Klerk JMH. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152:33–7.PubMedCrossRef
12.
go back to reference Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115–20.PubMed Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115–20.PubMed
13.
go back to reference Cooper DS, Doherty GM, Haugen BR, Kloss RT, Lee S, Mandel S, et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.PubMedCrossRef Cooper DS, Doherty GM, Haugen BR, Kloss RT, Lee S, Mandel S, et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.PubMedCrossRef
14.
go back to reference Gerard SK, Park HM. Stunning and I-123 Use for Diagnostic Whole Body Scanning. Thyroid. 2006;16:817.PubMedCrossRef Gerard SK, Park HM. Stunning and I-123 Use for Diagnostic Whole Body Scanning. Thyroid. 2006;16:817.PubMedCrossRef
15.
go back to reference Postgard P, Himmelmann J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002;43:818–34. Postgard P, Himmelmann J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002;43:818–34.
16.
go back to reference Ambesi-Impiombato FS, Parks LAM, Coon HG. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci U S A. 1980;77:3455–9.PubMedCrossRef Ambesi-Impiombato FS, Parks LAM, Coon HG. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci U S A. 1980;77:3455–9.PubMedCrossRef
17.
go back to reference Weiss SJ, Philip NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090–8.PubMed Weiss SJ, Philip NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090–8.PubMed
18.
go back to reference Grollman EF, Smolar A, Tombaccini D, Santisteban P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology. 1986;118:2477–82.PubMedCrossRef Grollman EF, Smolar A, Tombaccini D, Santisteban P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology. 1986;118:2477–82.PubMedCrossRef
19.
go back to reference Eng PH, Cardona GR, Previti MC, Chin WW, Braverman LE. Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol. 2001;144:139–44.PubMedCrossRef Eng PH, Cardona GR, Previti MC, Chin WW, Braverman LE. Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol. 2001;144:139–44.PubMedCrossRef
20.
go back to reference Leer LM, Ossendorp FA, de Vijlder JJM. TSH action on iodination in FRTL-5 cells. Horm Metab Res Suppl. 1990;23:43–6.PubMed Leer LM, Ossendorp FA, de Vijlder JJM. TSH action on iodination in FRTL-5 cells. Horm Metab Res Suppl. 1990;23:43–6.PubMed
21.
go back to reference Weiss SJ, Philip NJ, Ambesi-Impiombato FS, Grollman EF. Thyrotropin-stimulated iodide transport mediated by cyclic AMP and dependent on protein synthesis. Endocrinology. 1984;114:1099–107.PubMed Weiss SJ, Philip NJ, Ambesi-Impiombato FS, Grollman EF. Thyrotropin-stimulated iodide transport mediated by cyclic AMP and dependent on protein synthesis. Endocrinology. 1984;114:1099–107.PubMed
22.
go back to reference Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I− symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272:27230–8.PubMedCrossRef Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I− symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272:27230–8.PubMedCrossRef
23.
go back to reference Meller B, Deisting W, Wenzel BE, Pethe A, Nadrowitz R, Meller J, et al. Increased Radioiodine Uptake of Thyroid Cell Cultures after External Irradiation. Strahlenther Onkol. 2006;182:30–6.PubMedCrossRef Meller B, Deisting W, Wenzel BE, Pethe A, Nadrowitz R, Meller J, et al. Increased Radioiodine Uptake of Thyroid Cell Cultures after External Irradiation. Strahlenther Onkol. 2006;182:30–6.PubMedCrossRef
24.
go back to reference Bauer R. Physikalische Grundlagen der Radioiodtherapie. In: Radiojodtherapie bei Schilddrüsenerkrankungen. Indikationen – Ergebnisse – Nebenwirkungen. pp 3–21. Ed G Buttermann. Frankfurt: pmi;1987. Bauer R. Physikalische Grundlagen der Radioiodtherapie. In: Radiojodtherapie bei Schilddrüsenerkrankungen. Indikationen – Ergebnisse – Nebenwirkungen. pp 3–21. Ed G Buttermann. Frankfurt: pmi;1987.
25.
go back to reference Wawschinek O, Eber O, Petek W, Wakönig P, Gürakar A. Bestimmung der Harniodausscheidung mittels einer modifizierten Cer-Arsenitmethode. Berichte der ÖGKC. 1985;8:13–5. Wawschinek O, Eber O, Petek W, Wakönig P, Gürakar A. Bestimmung der Harniodausscheidung mittels einer modifizierten Cer-Arsenitmethode. Berichte der ÖGKC. 1985;8:13–5.
26.
go back to reference Studer H, Ramelli F. Simple goiter and its variants: euthyroid and hyperthyroid multinodular goiters. Endocr Rev. 1982;3:40–61.PubMed Studer H, Ramelli F. Simple goiter and its variants: euthyroid and hyperthyroid multinodular goiters. Endocr Rev. 1982;3:40–61.PubMed
27.
go back to reference Meller B, Haase A, Seyfarth M Richter E, Baehre M. Reduced radioiodine uptake at increased iodine intake and 131I-induced release of “cold” iodine stored in the thyroid. Nuklearmedizin. 2005;44:137–42.PubMed Meller B, Haase A, Seyfarth M Richter E, Baehre M. Reduced radioiodine uptake at increased iodine intake and 131I-induced release of “cold” iodine stored in the thyroid. Nuklearmedizin. 2005;44:137–42.PubMed
28.
go back to reference Meller B, von Hof K, Genina E, Deisting W, Meller J, Richter E, et al. Effects of 123I and 131I diagnostic activities and radioiodine therapy on urinary iodine excretion in patients with differentiated thyroid carcinoma. Nuklearmedizin. 2005;44:243–7.PubMed Meller B, von Hof K, Genina E, Deisting W, Meller J, Richter E, et al. Effects of 123I and 131I diagnostic activities and radioiodine therapy on urinary iodine excretion in patients with differentiated thyroid carcinoma. Nuklearmedizin. 2005;44:243–7.PubMed
29.
go back to reference Schomacker K, Wellner U, Scheidhauer K, Gabruk-Szostak B, Fischer T, Steinbach J, et al. Relationship between properties of 131I therapy and radioiodine kinetics. Nuklearmedizin. 1996;35:175–80.PubMed Schomacker K, Wellner U, Scheidhauer K, Gabruk-Szostak B, Fischer T, Steinbach J, et al. Relationship between properties of 131I therapy and radioiodine kinetics. Nuklearmedizin. 1996;35:175–80.PubMed
30.
go back to reference Nuchel C, Boddenberg B, Schicha H. The importance of the radioiodine test for the calculation of the therapeutic dose in benign thyroid diseases. Nuklearmedizin. 1993;32:91–8.PubMed Nuchel C, Boddenberg B, Schicha H. The importance of the radioiodine test for the calculation of the therapeutic dose in benign thyroid diseases. Nuklearmedizin. 1993;32:91–8.PubMed
31.
go back to reference Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid. 1999;9:821–30.PubMed Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid. 1999;9:821–30.PubMed
32.
go back to reference Appelskog IB, Ammerpohl O, Svechnikova IG, Lui WO, Almqvist PM, Ekstrom TJ. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. Int J Oncol. 2004;24:1419–25.PubMed Appelskog IB, Ammerpohl O, Svechnikova IG, Lui WO, Almqvist PM, Ekstrom TJ. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. Int J Oncol. 2004;24:1419–25.PubMed
33.
go back to reference Fareh J, Martel R, Kermani P Leclerc G. Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: a dose–response study. Circulation. 1999;99:1477–84.PubMed Fareh J, Martel R, Kermani P Leclerc G. Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: a dose–response study. Circulation. 1999;99:1477–84.PubMed
34.
go back to reference Klett R, Puille M, Steiner D, Bauer R. Einfluss des Applikationsabstandes auf den thyreoidalen Uptake bei zweizeitiger Radiojodtherapie. Nuklearmedizin. 2000;39:A91. Klett R, Puille M, Steiner D, Bauer R. Einfluss des Applikationsabstandes auf den thyreoidalen Uptake bei zweizeitiger Radiojodtherapie. Nuklearmedizin. 2000;39:A91.
35.
go back to reference Schumm-Draeger PM. Sodium/iodide symporter (NIS) and cytokines. Exp Clin Endocrinol Diabetes. 2001;109:32–4.PubMedCrossRef Schumm-Draeger PM. Sodium/iodide symporter (NIS) and cytokines. Exp Clin Endocrinol Diabetes. 2001;109:32–4.PubMedCrossRef
36.
go back to reference Arturi F, Presta I, Scarpelli D, Bidart J-M, Schlumberger M, Filetti S, et al. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. Eur J Endocrinol. 2002;147:655–61.PubMedCrossRef Arturi F, Presta I, Scarpelli D, Bidart J-M, Schlumberger M, Filetti S, et al. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. Eur J Endocrinol. 2002;147:655–61.PubMedCrossRef
37.
go back to reference Arai M, Tsushima T, Isozaki O Demura H, Shizume K, Emoto N, et al. Effects of transforming growth factor alpha (TGF-alpha) on DNA synthesis and thyrotropin-induced iodine metabolism in cultured porcine thyroid cells. Eur J Endocrinol. 1995;132:242–8.PubMed Arai M, Tsushima T, Isozaki O Demura H, Shizume K, Emoto N, et al. Effects of transforming growth factor alpha (TGF-alpha) on DNA synthesis and thyrotropin-induced iodine metabolism in cultured porcine thyroid cells. Eur J Endocrinol. 1995;132:242–8.PubMed
Metadata
Title
Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway
Authors
Birgit Meller
Erzsébet Gaspar
Wibke Deisting
Barbara Czarnocka
Manfred Baehre
Björn E. Wenzel
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0666-0

Other articles of this Issue 6/2008

European Journal of Nuclear Medicine and Molecular Imaging 6/2008 Go to the issue